In the trial of Impassion 050, atezolizumab with neoadjuvant dose-dense doxorubicin/cyclophosphamide–paclitaxel and pertuzumab-trastuzumab did not increase pathologic complete response rates compared to placebo in patients with high-risk, HER2+early-stage breast cancer, including patients with PD-L1+ breast cancer (57). Here, CD274 is linked to breast carcinoma.